Crinetics Pharmaceuticals (CRNX) has drawn fresh attention after reporting second quarter 2026 results on 3 August. Revenue reached US$25.12 million, while the company reported a net loss of US$120.86 million for the period.

The latest results arrived after a period of strong price gains, with Crinetics Pharmaceuticals trading at US$84.70 and showing a 90 day share price return of 130.35%. The 1 year total shareholder return is 175.72%, which points to momentum that has been building for some time around the company’s pipeline and risk profile.

If this kind of move has your attention, it could be a good moment to broaden your watchlist using a screener focused on emerging healthcare opportunities such as 44 healthcare AI stocks.

Crinetics Pharmaceuticals now combines growing revenue with a sizeable net loss and a share price that has moved sharply higher in a short period. The next step is to ask whether that mix is already fully reflected in the valuation.

Most Popular Narrative: 1% Undervalued

The most followed narrative currently places Crinetics Pharmaceuticals at a fair value of $85.50, which is slightly above the last close at $84.70. That small gap rests on a detailed set of growth and profitability assumptions that go well beyond the recent share price move.

The analysts have a consensus price target of $85.5 for Crinetics Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $540.9 million, earnings will come to $116.1 million, and it would be trading on a PE ratio of 116.9x, assuming you use a discount rate of 7.1%.

Want to see what sits behind that valuation for Crinetics Pharmaceuticals? The narrative leans on rapid revenue compounding, a major margin shift and a premium future earnings multiple. Curious which specific growth and profitability paths need to line up?

Result: Fair Value of $85.50 (ABOUT RIGHT)

However, there are still clear risks for Crinetics Pharmaceuticals, including potential setbacks in its broad endocrine pipeline and the chance that the Vertex deal terms could change.

Next Steps

With both risks and rewards in play for Crinetics Pharmaceuticals, this is a moment to move quickly and stress test the story against the numbers using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Crinetics Pharmaceuticals?

Do not stop with just one stock. Broaden your opportunity set now and let the Simply Wall Street screener surface ideas you might otherwise miss.

• Target potential upside by checking companies that look mispriced on fundamentals through the 50 high quality undervalued stocks.
• Strengthen your income stream by scanning for reliable cash return opportunities using the 10 dividend fortresses.
• Reduce portfolio stress by focusing on businesses with sturdier finances via the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.